Systimmune received IND clearance from the FDA for SI-B037, a bispecific antibody designed to target immunosuppression and other synergistic mechanisms, the company said. The clearance enables the company to proceed with planned clinical development in the United States. Bispecific antibodies that combine immunosuppressive pathway targeting with supportive biology are increasingly common as developers look to address immune resistance mechanisms in solid and hematologic tumors. For the biotech pipeline, IND clearance is an actionable milestone—moving a program from preclinical validation into human dosing, where safety, target engagement, and early pharmacodynamic markers will determine whether the asset can progress. Market attention will likely focus on the first cohort design and how SI-B037’s mechanism translates into measurable effects in tumor or immune microenvironments early in treatment.